Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Gilteritinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 known ✓ | P36888 | 14/20 | 1.00 |
| ▸ | AXL known ✓ | P30530 | 2/20 | 1.00 |
| ▸ | EML4 | Q9HC35 | 13/20 | 1.00 |
| ▸ | ALK | Q9UM73 | 13/20 | 1.00 |
| ▸ | RET | P07949 | 12/20 | 1.00 |
| ▸ | ROS1 | P08922 | 12/20 | 1.00 |
| ▸ | ETV6 | P41212 | 2/20 | 1.00 |
| ▸ | BMPR1B | O00238 | 1/20 | 1.00 |
| ▸ | PLK4 | O00444 | 1/20 | 1.00 |
| ▸ | CIT | O14578 | 1/20 | 1.00 |
| ▸ | AURKA | O14965 | 1/20 | 1.00 |
| ▸ | GAK | O14976 | 1/20 | 1.00 |
| ▸ | EPHB6 | O15197 | 1/20 | 1.00 |
| ▸ | RIPK2 | O43353 | 1/20 | 1.00 |
| ▸ | BUB1 | O43683 | 1/20 | 1.00 |
| ▸ | SNRNP200 | O75643 | 1/20 | 1.00 |
| ▸ | STK16 | O75716 | 1/20 | 1.00 |
| ▸ | STK10 | O94804 | 1/20 | 1.00 |
| ▸ | MAP4K4 | O95819 | 1/20 | 1.00 |
| ▸ | LATS1 | O95835 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gilteritinib SCHEMBL29432551 | 1.00 | FLT3 (1.00) | FLT3EML4ALKRETROS1 | |
| Gilteritinib SCHEMBL29355822 | 1.00 | FLT3 (1.00) | FLT3EML4ALKRETROS1 | |
| SCHEMBL328303 | 0.97 | FLT3 (0.94) | FLT3EML4ALKRETROS1 | |
| Gilteritinib SCHEMBL21819929 | 0.96 | FLT3 (1.00) | FLT3EML4ALKRETROS1 | |
| Gilteritinib SCHEMBL29357951 | 0.96 | FLT3 (1.00) | FLT3EML4ALKRETROS1 | |
| SCHEMBL29157675 | 0.96 | FLT3 (0.92) | FLT3EML4ALKRETROS1 | |
| Gilteritinib SCHEMBL22684910 | 0.95 | FLT3 (0.91) | FLT3EML4ALKRETROS1 | |
| Gilteritinib SCHEMBL22684912 | 0.95 | FLT3 (0.91) | FLT3EML4ALKRETROS1 | |
| SCHEMBL22652336 | 0.94 | FLT3 (0.89) | FLT3EML4ALKRETROS1 | |
| SCHEMBL21455071 | 0.94 | FLT3 (0.89) | FLT3EML4ALKRETROS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 199 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11944620-B2 | Stable pharmaceutical composition for oral administration | ASTELLAS PHARMA INC. (JP) | 2024-04-02 | — | — | US | claimed |
| US-11938133-B2 | Stable pharmaceutical composition for oral administration | ASTELLAS PHARMA INC. (JP) | 2024-03-26 | — | — | US | claimed |
| US-11938130-B2 | Stable pharmaceutical composition for oral administration | ASTELLAS PHARMA INC. (JP) | 2024-03-26 | — | — | US | claimed |
| US-11938132-B2 | Stable pharmaceutical composition for oral administration | ASTELLAS PHARMA INC. (JP) | 2024-03-26 | — | — | US | claimed |
| US-11938131-B2 | Stable pharmaceutical composition for oral administration | ASTELLAS PHARMA INC. (JP) | 2024-03-26 | — | — | US | claimed |
| US-11925638-B2 | Pharmaceutical composition comprising diamino heterocyclic carboxamide compound as active ingredient | ASTELLAS PHARMA INC. (JP) | 2024-03-12 | — | — | US | claimed |
| US-20230310422-A1 | STABLE PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION | ASTELLAS PHARMA INC. (JP) | 2023-10-05 | — | — | US | claimed |
| US-20230301992-A1 | STABLE PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION | ASTELLAS PHARMA INC. (JP) | 2023-09-28 | — | — | US | claimed |
| US-20230277531-A1 | STABLE PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION | ASTELLAS PHARMA INC. (JP) | 2023-09-07 | — | — | US | claimed |
| US-20230277532-A1 | STABLE PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION | ASTELLAS PHARMA INC. (JP) | 2023-09-07 | — | — | US | claimed |
| EP-3103453-A1 | MEDICINAL COMPOSITION COMPRISING DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND AS ACTIVE INGREDIENT | Astellas Pharma Inc. (JP) | 2016-12-14 | — | — | EP | claimed |
| US-20160339020-A1 | PHARMACEUTICAL COMPOSITION COMPRISING DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND AS ACTIVE INGREDIENT | ASTELLAS PHARMA INC. (JP) | 2016-11-24 | — | — | US | claimed |
| US-9487491-B2 | Diamino heterocyclic carboxamide compound | ASTELLAS PHARMA INC. (JP) | 2016-11-08 | — | — | US | claimed |
| EP-2428508-B9 | DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND | ASTELLAS PHARMA INC (JP) | 2016-04-20 | — | — | EP | claimed |
| EP-3009428-A1 | DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND | Astellas Pharma Inc. (JP) | 2016-04-20 | — | — | EP | claimed |
| EP-2428508-B1 | DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND | ASTELLAS PHARMA INC (JP) | 2015-12-16 | — | — | EP | claimed |
| US-8969336-B2 | Diamino heterocyclic carboxamide compound | ASTELLAS PHARMA INC. (JP) | 2015-03-03 | — | — | US | claimed |
| US-20140371196-A1 | DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2014-12-18 | — | — | US | claimed |
| EP-2428508-A1 | DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND | Astellas Pharma Inc. (JP) | 2012-03-14 | — | — | EP | claimed |
| US-20120040968-A1 | DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND | WATERS TECHNOLOGIES CORPORATION (US) | 2012-02-16 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140371196-A1 | DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND | EML4, ALK, ERBB4 | FLT3 5/4885AXL 22/4885EML4 1/4885 |
| US-11938133-B2 | Stable pharmaceutical composition for oral administration | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, SLC20A1, RCC1 | FLT3 2633/4885AXL 3599/4885EML4 1483/4885 |
| US-11938131-B2 | Stable pharmaceutical composition for oral administration | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, RCC1, SLC34A1 | FLT3 2129/4885AXL 3294/4885EML4 1383/4885 |
| US-11925638-B2 | Pharmaceutical composition comprising diamino heterocyclic carboxamide compound as active ingredient | AXL, FLT3, MERTK | FLT3 2/4885AXL 1/4885EML4 3383/4885 |
| US-20230277531-A1 | STABLE PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, SLC20A1, RCC1 | FLT3 2633/4885AXL 3599/4885EML4 1483/4885 |
| US-11938132-B2 | Stable pharmaceutical composition for oral administration | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, SLC20A1, RCC1 | FLT3 2633/4885AXL 3599/4885EML4 1483/4885 |
| US-20230301992-A1 | STABLE PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, SLC20A1, RCC1 | FLT3 2633/4885AXL 3599/4885EML4 1483/4885 |
| US-20120040968-A1 | DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND | EML4, ALK, ERBB4 | FLT3 5/4885AXL 22/4885EML4 1/4885 |
| US-11938130-B2 | Stable pharmaceutical composition for oral administration | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, SLC20A1, RCC1 | FLT3 2633/4885AXL 3599/4885EML4 1483/4885 |
| US-20230310422-A1 | STABLE PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, SLC20A1, RCC1 | FLT3 2633/4885AXL 3599/4885EML4 1483/4885 |
| US-20160339020-A1 | PHARMACEUTICAL COMPOSITION COMPRISING DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND AS ACTIVE INGREDIENT | AXL, FLT3, MERTK | FLT3 2/4885AXL 1/4885EML4 3383/4885 |
| US-20230277532-A1 | STABLE PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, SLC20A1, RCC1 | FLT3 2633/4885AXL 3599/4885EML4 1483/4885 |
| US-11944620-B2 | Stable pharmaceutical composition for oral administration | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, SLC20A1, RCC1 | FLT3 2633/4885AXL 3599/4885EML4 1483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.